PURPOSE OF REVIEW: This review
focuses on recent developments in understanding regulation of leukocyte transendothelial migration by small GTPase
signaling. RECENT FINDINGS: New studies are refining the model for GTPase regulation of leukocyte-endothelial cell
interactions that occur during leukocyte transmigration. An emerging theme is
that the endothelial cell is an active participant in this process; an example
of this is the identification of a novel leukocyte docking structure. The role of
second messengers such as reactive oxygen species downstream and the
involvement of kinases such as Pyk2 and Tec kinases upstream of GTPase
activation is becoming appreciated. In the leukocyte, finer distinctions
between closely related GTPases like Rac1 and Rac2
are being made, and a new role for RhoH has been
characterized. Finally, the focus on Rap1 as a key regulator of leukocyte integrin-dependent adhesion is expanding to include roles
in endothelial cell-cell adhesion and junctional
regulation during transmigration. SUMMARY: Understanding the complex series of
events involved in cell-cell interactions during leukocyte transendothelial
migration is a prerequisite for designing novel therapies to treat clinical
conditions in which an inappropriate inflammatory response leads to disease. A
discussion is provided of recent developments in the molecular regulation of
leukocyte recruitment.
The cell adhesion molecule
VCAM-1 plays an important role in regulation of inflammation in
atherosclerosis, asthma, inflammatory bowel disease, or transplantation. VCAM-1
activates endothelial cell NADPH oxidase and this oxidase activity is required for VCAM-1-dependent
lymphocyte migration. We previously reported that a mouse microvascular
endothelial cell line promotes lymphocyte migration that is dependent on VCAM-1
but not on other known adhesion molecules. Here we have investigated the
signaling mechanisms underlying VCAM-1 function. Lymphocyte binding to VCAM-1
on the endothelial cell surface activated an endothelial cell calcium flux that
could be inhibited with anti-alpha 4-integrin and mimicked by
anti-VCAM-1-coated beads. VCAM-1 stimulation of calcium responses could be
blocked by an intracellular calcium mobilization inhibitor, a calcium channel
inhibitor, or a calcium chelator, resulting in the
inhibition of NADPH oxidase activity. Addition of ionomycin overcame the calcium channel blocker-suppressed,
VCAM-1-stimulated NADPH oxidase activity, but could
not reverse the inhibitory effect imposed by intracellular calcium blockage,
indicating that both intracellular and extracellular
calcium mobilizations are required for VCAM-1-mediated activation of NADPH oxidase. Furthermore, VCAM-1 specifically activated the Rho
family GTPase Rac1 and VCAM-1 activation of NADPH oxidase was blocked by a dominant negative Rac1. Thus,
VCAM-1 stimulates the mobilization of intracellular and extracellular
calcium and Rac1 activity which are required for the activation of NADPH oxidase.